NCT05576818RecruitingPhase 3
Effect of Synbiotic as an Adjuvant Therapy in the Treatment of Parkinson's Disease
Clinical Study Evaluating the Efficacy and Safety of Synbiotic as an Adjuvant Therapy in the Treatment of Parkinson's Disease
Source: ClinicalTrials.gov · Last updated 10 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study aims to investigate the possible efficacy and safety of synbiotic preparation of Lactobacillus acidophilus probiotic with prebiotic fibers as an adjuvant therapy in the treatment of Parkinson's disease
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 66 (estimated)
- First submitted
- 10 Oct 2022
- Start date
- 30 Jun 2022
- Primary completion date
- Jun 2025
- Lead sponsor
- Tanta University
- Diseases
- Parkinson disease
- NCT number
- NCT05576818
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 66
- From 30 Jun 2022 to the primary completion date, Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who are currently using or used antibiotics therapy in the preceding month
- Patients who are currently using or used other probiotic products in the preceding two weeks
- Patients scheduled to undergo GIT surgery or those underwent GIT surgery
- Patients receiving artificial enteral or intravenous nutrition
- Patients taking antioxidant and/or anti-inflammatory medications
Other illness
- Patients with Known allergy to probiotics
- Patients with inflammatory condition and/or condition involving oxidative stress
Other
- Patients with depression and/or psychosis
- Patients with Hyperthyroidism
- Smokers
- Modified Hoehn \& Yahr stage MHY 5
Who the study is looking for
- Age between 45 and 65 years old
- Both sexes
- Patients with Parkinson's disease on dopamine replacement therapy
- Modified Hoehn and Yahr stage, MHY 1-4
Age in the registry: 45 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tanta university Coordinator of this site? Confirm its status | Tanta | Egypt | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.